小剂量红霉素长期口服佐治支气管扩张症稳定期患者效果评估  

Effect evaluation of long-term low-dose oral administration of erythromycin on patients with bronchiectasis in stable period

作　　者：杨凤霞 

机构地区：[1]陕西省延安市洛川县计划生育服务站,陕西延安727400

出　　处：《临床医学研究与实践》2017年第2期8-9,共2页Clinical Research and Practice

摘　　要：目的分析小剂量红霉素长期口服在支气管扩张症稳定期的应用效果。方法随机选取27例支气管扩张症稳定期患者作为治疗组,给予口服红霉素肠溶片治疗;另选取27例作为对照组,给予口服安慰剂治疗。比较两组患者的临床效果。结果治疗后,治疗组患者痰细菌清除率为44.0%,对照组患者痰细菌清除率为4.55%,差异显著(P<0.05);用药半年后,对照组患者FVC、FEV1指标与治疗前比较无明显变化,而治疗组患者FVC、FEV1指标均有所上升,差异具有统计学意义(P<0.05);治疗组患者治疗期间急性加重次数为(2.34±0.53)次,对照组患者治疗期间急性加重次数为(5.27±0.49)次,差异显著(P<0.05)。结论支气管扩张症稳定期患者在常规药物治疗条件下长期服用小剂量红霉素,可改善肺功能,降低急性发作次数,提高患者生活质量。Objective To analyze the effect of long-term low-dose oral administration of erythromycin on patients with bronehiectasis in stable period. Methods Twenty-seven patients with bronchiectasis in stable period were randomly selected as the treatment group and accepted erythromycin enteric-coated tablets. The other 27 patients were randomly selected as the control group and accepted oral placebo. The clinical effects of the two groups were compared. Results After treatment, the bacterial clearance rate of sputum in the treatment group was 44.00%, and in the control group was 4.55%, there was significant difference between the two groups （P〈0.05）. Six months after treatment, FVC and FEVI of the control group had no significant change compared with those before treatment, while the FVC and FEVx indexes of the treatment group increased, the difference was statistically significant （P〈0.05）. The number of acute attacks in the treatment group was （2.34±0.53） and in the control group it was （5.27±0.49）, the difference was significantly difference in the two groups （P〈 0.05）. Conclusion Under conventional drug therapy, long-term low-dose oral administration of erythromycin in patients with stable bronchodilator can improve lung function, reduce the time of acute attacks, and improve the quality of life of

关 键 词：小剂量红霉素 安慰剂 支气管扩张症稳定期 

分 类 号：R562.22[医药卫生—呼吸系统]